http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-I639599-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_96ec3985e3ce9b24614fb87bf51a4f12 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-635 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
| filingDate | 2012-03-28^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-11-01^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2fd73b265c03fc1e0e8562a81f1bd445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32f65874f3dcca5ef4b8204afda04f0f |
| publicationDate | 2018-11-01^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | TW-I639599-B |
| titleOfInvention | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazoline |
| abstract | The present invention relates to:-2,3-dihydroimidazo [1,2-c] quinazoline compound, or a pharmaceutical composition containing the compound as the sole active agent, or a) the compound or a pharmaceutical combination containing the compound The use of a combination of a substance and b) one or more other active agents, which is used to prepare a drug for treating or preventing cancer;-a) the compound and b) one or more other active agents;-comprising the compound A pharmaceutical composition for treating breast cancer as the sole active agent;-a pharmaceutical composition comprising a) the compound in combination with b) one or more other active agents;-expression with Bcl, HER family expression and / or activation, PIK3CA signal Use of biomarkers related to changes in conduction and / or loss of PTEN for predicting the sensitivity and / or resistance of cancer patients to the compound and providing a principle-based synergistic combination as defined herein to increase sensitivity Sexual and / or overcome resistance; andn-A method for determining the component content of one or more of Bcl expression, HER family expression and / or activation, PIK3CA signaling and / or PTEN loss. |
| priorityDate | 2011-04-05^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 1000 of 1562.
| Next Page | Last Page |